Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -184.07% is 13% below its 2-year average of -162.30%, near the low end of its 2-year range (-248.67%–6.81%).
19.77% below its 12-month average of -153.69%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -203.79%.
EBITDA MARGIN
-184.07%
EBITDA MARGIN AVG TTM
-153.69%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-19.77%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$322.71M
EBITDA Margin
-56.12%
TTM Avg
-71.22%
3Y Avg
-76.13%
5Y Avg
-77.81%
Market Cap
$321.76M
EBITDA Margin
11.45%
TTM Avg
4.69%
3Y Avg
-3.39%
5Y Avg
-11.89%
Market Cap
$330.19M
EBITDA Margin
-59.31%
TTM Avg
-58.08%
3Y Avg
-69.87%
5Y Avg
-66.91%
Market Cap
$318.43M
EBITDA Margin
-285.23%
TTM Avg
-308.13%
3Y Avg
-415.00%
5Y Avg
-335.56%
Market Cap
$309.19M
EBITDA Margin
-24933.33%
TTM Avg
-24426.94%
3Y Avg
-19832.71%
5Y Avg
-13250.84%
Market Cap
$344.04M
EBITDA Margin
-870.38%
TTM Avg
-506.32%
3Y Avg
-506.32%
5Y Avg
-506.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $324.76M | -184.07% | -153.69% | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $322.71M | -56.12% | -71.22% | -76.13% | -77.81% |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | 11.45% | 4.69% | -3.39% | -11.89% |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | -59.31% | -58.08% | -69.87% | -66.91% |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | -285.23% | -308.13% | -415.00% | -335.56% |
| Agenus Inc. (AGEN)vs › | $311.90M | -9.24% | -56.39% | -95.53% | -82.66% |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | -24933.33% | -24426.94% | -19832.71% | -13250.84% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | -870.38% | -506.32% | -506.32% | -506.32% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
Gross Margin
50.9%
EBITDA Margin
-184.1%
Operating Margin
-188.3%
Net Margin
-214.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -203.79% |
| 2026-03-31 | -248.67% |
| 2025-12-31 | -186.73% |
| 2025-09-30 | 6.81% |
| 2025-06-30 | -136.05% |
| 2025-03-31 | -188.47% |
| 2024-12-31 | -130.42% |
| 2024-09-30 | -191.23% |
| 2024-06-30 | -180.87% |
| 2024-03-31 | -163.57% |
